The Food and Drug Administration approved a novel engineered viral immunotherapy for patients with treatment-resistant advanced melanoma on Aug. 6.
The therapy represents a new class of cancer treatment — engineered oncolytic viruses — distinct from checkpoint inhibitors, targeted therapies and chemotherapy, according to FDA. The approval was granted for patients whose cancer has not responded to existing treatments.
Oncolytic viral therapies work by using modified viruses to selectively infect and destroy cancer cells while stimulating the immune system to attack tumors. The approach has been in development for years, and this approval marks a significant validation of the platform.
Melanoma is the deadliest form of skin cancer. The American Cancer Society has estimated roughly 100,000 new cases and 8,000 deaths from melanoma annually in recent years.
For patients with advanced melanoma that has resisted conventional treatments, the approval provides an additional option in a disease where treatment-resistant cases carry a poor prognosis. Patients with advanced melanoma that does not respond to immunotherapy or targeted therapy face limited alternatives.
The drug’s manufacturer and specific brand name were not captured in the available FDA release. Pricing and insurance coverage details were also not immediately available.
The approval signals FDA’s continued openness to innovative biologics platforms and could accelerate development of oncolytic viral therapies for other cancer types. Multiple engineered virus candidates are in clinical trials for various solid tumors.